- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Iclusig may find use in other cancers and '113 is better than the market believes.
Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.
Instead of selling stock whenever the wind blows, biotech execs should be buying.
The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.
How best to invest in the next important clinical trial catalyst facing Celgene.